The plant has been operating at 100 percent since this summer, but to boost its overall supply, the world’s main contrast dye supplier invested $80 million into increasing its contrast media production by 30 percent at its site in Lindesnes, Norway. The company planned the investment because of the predicted surge in global demand.
Kevin O’Neill, the president and CEO of GE Healthcare’s pharmaceutical diagnostics division, said in a statement the company expects demand for the product to double in the next 10 years because of the “global prevalence of chronic disorders and significant growth in CT procedures.”
Annually, healthcare providers perform about 300 million CT scans, but this was hindered during the summer after one facility closed, highlighting the vulnerability of the global supply of the iodine solution.
GE Healthcare said it plans to boost its contrast dye supply by 30 million more doses by 2025.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
